

# Elucidating the mechanism of action of benzodiazepine drugs: The role of hippocampal damage in the development of anterograde amnesia

**Xing Gao**

College of Life Sciences, Huzhou University, Huzhou, 313000, China

FelicityGX@outlook.com

**Abstract.** Benzodiazepines are often prescribed medications that are widely utilized for a variety of medical issues. The usage of benzodiazepines comes with a number of adverse effects, including anterograde amnesia, which can have a significant negative impact on a patient's life. This paper analyzes current amnesia cases and the mechanism of benzodiazepine-induced anterograde amnesia in order to determine how benzodiazepines cause anterograde amnesia. This paper focuses on the mechanism by which benzodiazepines impede long-term potentiation (LTP) by reducing glutamate release and enhancing the inhibitory effect of gamma-aminobutyric acid (GABA) on n-methyl-D-aspartate (NMDA) receptors. The end outcome of this interference is anterograde amnesia. Additionally, this paper gives some suggestions on the use of benzodiazepines and the future research direction. It highlights the necessity of more study to comprehend the underlying mechanisms in greater detail and to develop alternate therapies that lessen the negative consequences on cognition.

**Keywords:** Anterograde amnesia, Benzodiazepines, GABA, NMDA receptor, LTP.

## 1. Introduction

Benzodiazepine drugs, also called benzodiazepines, are a class of medications that are common practice in clinical settings. They are utilized to treat a range of symptoms and conditions, such as anxiety disorders, post-traumatic stress disorder, obsessive-compulsive disorder, and others [1]. Benzodiazepines (Phenazepam), diazepam, and lorazepam are some of the most common members of this class of medications.

Research by Rowlett et al. discovered that benzodiazepines may trigger many kinds of negative side effects, including paraphilic amnesia, sedation, drowsiness, impaired cognitive and psychomotor performance, and impaired motor coordination [2]. This paper mainly discusses the mechanism of anterograde amnesia induced by benzodiazepines.

It is crucial to comprehend the pathophysiology of anterograde amnesia and how it relates to hippocampal injury. In a clinical setting, it aids in the diagnosis and treatment of patients with memory disorders. By identifying the specific brain regions involved in anterograde amnesia, healthcare professionals can develop targeted interventions to improve memory function in these individuals.

From a basic research perspective, studying anterograde amnesia and its association with hippocampal damage provides insights into the neural mechanisms underlying memory formation.

Investigating the effects of hippocampal damage on memory processes can help elucidate the specific functions of the hippocampus in memory formation and retrieval. This knowledge contributes to our broader understanding of how the brain processes and stores information.

This paper aims to provide a comprehensive understanding of how benzodiazepines impact memory consolidation processes. By elucidating these mechanisms, we can gain insights into the potential therapeutic strategies for mitigating the adverse effects of benzodiazepines on memory formation and consolidation.

## **2. Mechanism of Action of Benzodiazepine Drugs**

The main inhibitory neurotransmitter in the brain is gamma-aminobutyric acid (GABA), which functions by attaching to GABA receptors. The majority of this paper deals with the binding to GABA-A receptors. Inhibitory neurotransmission is mediated by these receptors, which are ligand-gated ion channels [3]. Ion channels are opened when GABA interacts to the GABA-A receptor, enabling chloride ions to enter the neuron. Chloride ions cause the cell membrane to become hyperpolarized, which makes it harder for neurons to achieve the threshold for action potential firing [4].

Benzodiazepines enhance the effects of GABA by attaching to the benzodiazepine binding site on the GABA-A receptor complex, which is a particular location on the GABA-A receptor complex. This binding site is located to GABAergic inhibitory synapses [5]. When benzodiazepines attach to this location, they allosterically modify the receptor, boosting GABA's affinity for the receptor's binding site. This makes GABA more effective at opening the ion channel and raising chloride conductance, which amplifies the inhibitory impact [2].

## **3. Anterograde Amnesia**

Anterograde amnesia is a memory condition marked by the inability to create new memories or retain new knowledge after the onset of amnesia [6]. While Aggleton provides evidence supporting the claim that after a variety of types of brain trauma, anterograde amnesia may happen [7], the evidence from patient RB and other amnesia patients with bilateral damage contained to the hippocampal formation, as well as studies on experimental animals, strongly supports the claim that damage restricted to the hippocampal CA1 region is enough to cause anterograde amnesia [8].

Patients with anterograde amnesia may have intact short-term memory but struggle to store information in their long-term memory storage [9]. This could make it difficult to recall recent encounters, conversations, or new faces. They may repeatedly ask the same questions or engage in repetitive behaviors due to their inability to retain new information. It may require individuals to rely significantly on outside resources, like calendars, notes, and reminders, to make up for their memory deficiencies. The inability to form new memories can also lead to frustration, anxiety, and a sense of disorientation [10].

## **4. The Hippocampus in Memory Formation**

The hippocampus is a crucial component of the brain responsible for many different cognitive processes, including memory consolidation. Memory consolidation is the conversion of fresh memories into long-term memories. According to Frankland & Bontempi (2005), the hippocampus is initially engaged in the development of memories in the medial temporal lobe system. As memories mature, they rely more and more on other parts of the brain, such as the cortex. This suggests that the hippocampus is engaged in the initial encoding and consolidation of memories, while other brain regions, such as the cortex, are in charge of long-term memory storage and retrieval [11].

Long-term potentiation (LTP) within the hippocampus has been implicated in memory consolidation [12]. The N-methyl-D-aspartate (NMDA) receptor complex is what causes the most well-studied kind of LTP in the hippocampus.

NMDA receptors are a subclass of glutamate receptors that are highly permeable to calcium ions ( $\text{Ca}^{2+}$ ). When NMDA receptors are activated by the attachment of glutamate and the dissolution of the magnesium barrier, calcium ions enter the postsynaptic neuron through the open channels [13]. Calcium

binds to calmodulin, which then activates Calmodulin-dependent protein kinase II (CaMKII). Activated CaMKII moves to the synapses, where it combines to the NMDA receptors and generates potentiation by phosphorylating the primary and auxiliary subunits of  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors [14]. As a result of this phosphorylation, AMPA receptors get embedded into the postsynaptic membrane, enhancing synaptic transmission and contributing to the strengthening of synaptic connections, which stabilizes long-term memory [15].

In addition to the CaMKII pathway, other signaling pathways and molecules are also involved in the mechanism of LTP and memory consolidation. These include protein kinase C (PKC), cyclic adenosine monophosphate (cAMP), and transcriptional regulators such as cAMP response element-binding protein (CREB). These signaling pathways contribute to the phosphorylation of target proteins, modulation of synaptic strength, and long-term changes in gene expression necessary for memory consolidation [16].

Furthermore, the mitogen-activated protein kinase (MAPK) pathway can be triggered by calcium influx through NMDA receptors [17]. The MAPK pathway is involved in cellular processes such as gene expression, synaptic plasticity, and neuronal survival. Activation of this pathway can lead to the phosphorylation of transcription factors and the initiation of gene transcription, which ultimately contributes to the long-lasting changes associated with LTP.

Additionally, NMDA receptor activation and calcium influx can trigger the dispersion of SynGAP, a Ras-GTPase activating protein, from synaptic spines. This dispersion is reliant on CaMKII phosphorylating SynGAP. The dispersion of SynGAP leads to the insertion of AMPA receptors, expansion of the spine, and strengthening of the synapses during LTP [18].

Moreover, recent studies have highlighted the significance of dendritic NMDA spikes in the production of LTP. Dendritic NMDA spikes, which are calcium transients unique to regenerating branches, contribute to the critical postsynaptic depolarization required for associative LTP. These spikes can serve as synaptic input amplifiers that are cell-intrinsic and are correlated with synaptic LTP induction [19].

## **5. Benzodiazepine-Induced Anterograde Amnesia**

Benzodiazepines have been demonstrated to impair long-term potentiation (LTP) in the hippocampus, supporting the idea that these drugs can interfere with the mechanisms underlying memory formation [20].

One mechanism by which benzodiazepines disrupt LTP is through their effects on the N-methyl-D-aspartate (NMDA) receptor complex. Through the previously mentioned method, benzodiazepines enhance the inhibitory effects of gamma-aminobutyric acid (GABA), resulting in an increase in chloride ion influx into neurons. This increase in negative charge causes the postsynaptic membrane to become hyperpolarized, making it more difficult for NMDA receptors to depolarize the membrane and generate an excitatory response [5].

Additionally, GABA-A receptor activation can induce a fall in intracellular pH (pHi), which can inhibit NMDA receptor function. When GABA-A receptors are activated, bicarbonate ( $\text{HCO}_3^-$ ) conductance is also activated, which results in the efflux of bicarbonate ions and a decrease in pHi. This fall in pHi can modulate the activity of NMDA receptors and contribute to their inhibition [21]. By inhibiting NMDA receptors, benzodiazepines interfere with the normal processes of LTP induction, leading to impaired memory formation and subsequent anterograde amnesia.

Another mechanism involves the reduction of glutamate release in the hippocampus. At the presynaptic level, GABA inhibits the release of glutamate by hyperpolarizing the presynaptic terminals and reducing the influx of calcium ions, which are necessary for neurotransmitter release.

At the postsynaptic level, the enhanced inhibitory actions of GABA can indirectly reduce glutamate release by inhibiting the excitatory neurons that provide feedback to the presynaptic terminals [22]. By reducing the release of glutamate, benzodiazepines disrupt the typical mechanism triggered by long-term potentiation (LTP), resulting in the inhibition of memory consolidation and subsequent development of anterograde amnesia.

## 6. Future Directions

Current studies introduced various strategies to mitigate memory impairment caused by benzodiazepine. One potential strategy is to adhere to recommendations for short-term prescribing of benzodiazepines. Suggests that benzodiazepine dependence could be prevented by limiting the duration of benzodiazepine use to 2-4 weeks, whenever possible [23]. This approach aims to minimize the risk of developing dependence and associated memory impairment.

Another strategy involves the judicious and individualized management of benzodiazepine withdrawal in dependent patients. Ashton (2005) emphasized that withdrawal from benzodiazepines can be feasible and need not be traumatic if managed carefully [24]. Gradual tapering of the benzodiazepine dosage under medical supervision may help minimize withdrawal symptoms and potential memory impairment.

Future research can explore alternative approaches to anxiolytic treatment that minimize memory-related side effects. One avenue for investigation is the development of novel pharmacological agents that target specific neurotransmitter systems or molecular signaling pathways involved in anxiety and memory processes. For example, researchers could explore the potential of developing drugs that selectively modulate GABA-A receptor subunits implicated in memory deficits, such as the  $\alpha 1$  and  $\alpha 5$  subunits.

Another direction for future research is the investigation of non-pharmacological interventions for anxiety that do not have significant memory-related side effects. Relaxation techniques, cognitive-behavioral therapy (CBT), and mindfulness-based stress reduction (MBSR) have shown promise in reducing anxiety symptoms without impairing memory function [25]. Further studies could explore the effectiveness of these interventions in different populations and examine their long-term effects on anxiety and memory.

## 7. Conclusion

Benzodiazepines exert their pharmacological effects by enhancing the inhibitory actions of gamma-aminobutyric acid (GABA) through positive regulation of GABA-A receptors. This modulation is brought about by binding to particular locations on the GABA-A receptor complex, increasing the frequency at which chloride ion channels open and hyperpolarization of the neuronal membrane. This regulatory mechanism leads to the influence of NMDA receptors and a decrease in glutamate release in the hippocampus, which impairs long-term potentiation (LTP) in the hippocampus, ultimately leading to the manifestation of anterograde amnesia.

When considering the use of benzodiazepines, it is crucial to take into account the broader context and carefully weigh the benefits and risks. While benzodiazepines can provide effective short-term relief for conditions such as anxiety and insomnia, they are associated with potential side effects, including anterograde amnesia. Prohibiting their use entirely may deprive patients of a valuable treatment option, but cautious prescribing practices, appropriate dosing, and regular monitoring are essential to mitigate the risks.

Furthermore, it is important to explore and promote alternative treatment options, such as cognitive-behavioral therapy and non-pharmacological interventions, which have shown efficacy in managing anxiety and insomnia without the cognitive side effects associated with benzodiazepines. These approaches can be used as first-line treatments or in combination with benzodiazepines to minimize the need for long-term use.

Further research is needed to enhance our understanding of memory modulation and promote safer pharmacological interventions. By conducting rigorous research, we can improve our understanding of the cognitive effects of benzodiazepines and develop evidence-based guidelines for their use. This will ultimately contribute to the development of safer and more effective pharmacological interventions for individuals who require treatment for anxiety, insomnia, and related conditions.

### Authors' Contributions

As the sole author of this paper, I provide a detailed analysis of the mechanisms by which benzodiazepine affects the hippocampus and leads to anterograde amnesia. I conducted a thorough search of the literature and synthesized the findings to provide a comprehensive overview of the current state of knowledge on the topic.

### Acknowledgments

I would like to express my gratitude to Doria for her guidance and support throughout the writing of this paper. Her insightful comments and feedback were invaluable in shaping the direction of this paper.

### References

- [1] A. Sarangi, T. McMahon, and J. Gude, 'Benzodiazepine Misuse: An Epidemic Within a Pandemic', *Cureus*, vol. 13, no. 6, p. e15816, Jun. 2021, doi: 10.7759/cureus.15816.
- [2] J. K. Rowlett, D. M. Platt, S. Lelas, J. R. Atack, and G. R. Dawson, 'Different GABA A receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates', *Proc. Natl. Acad. Sci. U.S.A.*, vol. 102, no. 3, pp. 915–920, Jan. 2005, doi: 10.1073/pnas.0405621102.
- [3] J. J. Kim and R. E. Hibbs, 'Direct structural insights into GABAA receptor pharmacology', *Trends Biochem Sci*, vol. 46, no. 6, pp. 502–517, Jun. 2021, doi: 10.1016/j.tibs.2021.01.011.
- [4] S. Nawafleh et al., 'GABA Receptors Can Depolarize the Neuronal Membrane Potential via Quantum Tunneling of Chloride Ions: A Quantum Mathematical Study', *Cells*, vol. 11, no. 7, p. 1145, Jan. 2022, doi: 10.3390/cells11071145.
- [5] J. Glykys and I. Mody, 'Activation of GABAA Receptors: Views from Outside the Synaptic Cleft', *Neuron*, vol. 56, no. 5, pp. 763–770, Dec. 2007, doi: 10.1016/j.neuron.2007.11.002.
- [6] L. Alessandro, M. Ricciardi, H. Chaves and R. F. Allegri, Acute amnesic syndromes, *Journal of the Neurological Sciences*, 413, 116781, 6 2020, doi: 10.1016/j.jns.2020.116781.
- [7] J. P. Aggleton, 'Looking beyond the hippocampus: old and new neurological targets for understanding memory disorders', *Proc. R. Soc. B.*, vol. 281, no. 1786, p. 20140565, Jul. 2014, doi: 10.1098/rspb.2014.0565.
- [8] M. Verfaellie and M. M. Keane, 'Memory disorders', in *APA handbook of neuropsychology, Volume 1: Neurobehavioral disorders and conditions: Accepted science and open questions*, Vol. 1, in *APA handbooks in psychology®*, Washington, DC, US: American Psychological Association, 2023, pp. 205–224. doi: 10.1037/0000307-010.
- [9] D. K. Detterman and N. R. Ellis, 'Determinants of induced amnesia in short-term memory.', *Journal of Experimental Psychology*, vol. 95, no. 2, pp. 308–316, 1972, doi: 10.1037/h0033629.
- [10] D. Hassabis, D. Kumaran, S. D. Vann, and E. A. Maguire, 'Patients with hippocampal amnesia cannot imagine new experiences', *Proc. Natl. Acad. Sci. U.S.A.*, vol. 104, no. 5, pp. 1726–1731, Jan. 2007, doi: 10.1073/pnas.0610561104.
- [11] P. W. Frankland and B. Bontempi, 'The organization of recent and remote memories', *Nat Rev Neurosci*, vol. 6, no. 2, pp. 119–130, Feb. 2005, doi: 10.1038/nrn1607.
- [12] M. Kyrke-Smith, L. J. Volk, S. F. Cooke, M. F. Bear, R. L. Huganir, and J. D. Shepherd, 'The Immediate Early Gene Arc Is Not Required for Hippocampal Long-Term Potentiation', *J. Neurosci.*, vol. 41, no. 19, pp. 4202–4211, May 2021, doi: 10.1523/JNEUROSCI.0008-20.2021.
- [13] V. Saini, A. Rani, A. Kumar, K. Jha, S. Karnati, and H. C. Jha, 'Altered synaptic plasticity: plausible mechanisms associated with viral infections', *Future Virology*, vol. 18, no. 11, pp. 733–752, Aug. 2023, doi: 10.2217/fvl-2023-0105.
- [14] A. M. Purkey and M. L. Dell'Acqua, 'Phosphorylation-Dependent Regulation of Ca<sup>2+</sup>-Permeable AMPA Receptors During Hippocampal Synaptic Plasticity', *Frontiers in Synaptic*

- Neuroscience, vol. 12, 2020, Accessed: Nov. 03, 2023. [Online]. Available: <https://www.frontiersin.org/articles/10.3389/fnsyn.2020.00008>
- [15] Q. L. Wu, Y. Gao, J.-T. Li, W.-Y. Ma, and N.-H. Chen, 'The Role of AMPARs Composition and Trafficking in Synaptic Plasticity and Diseases', *Cell Mol Neurobiol*, vol. 42, no. 8, pp. 2489–2504, Nov. 2022, doi: 10.1007/s10571-021-01141-z.
  - [16] E. R. Kandel, 'The Molecular Biology of Memory Storage: A Dialogue Between Genes and Synapses', *Science*, vol. 294, no. 5544, pp. 1030–1038, Nov. 2001, doi: 10.1126/science.1067020.
  - [17] Z. Liu, Q. Zhong, C. Tian, H. M. Ma, J. Yu, and S. Hu, 'NMDA receptor-driven calcium influx promotes ischemic human cardiomyocyte apoptosis through a p38 MAPK-mediated mechanism', *J of Cellular Biochemistry*, vol. 120, no. 4, pp. 4872–4882, Apr. 2019, doi: 10.1002/jcb.27702.
  - [18] M. Wu et al., 'Rho–Rho-Kinase Regulates Ras-ERK Signaling Through SynGAP1 for Dendritic Spine Morphology', *Neurochem Res*, vol. 47, no. 9, pp. 2757–2772, Sep. 2022, doi: 10.1007/s11064-022-03623-y.
  - [19] F. Brandalise, S. Carta, F. Helmchen, J. Lisman, and U. Gerber, 'Dendritic NMDA spikes are necessary for timing-dependent associative LTP in CA3 pyramidal cells', *Nat Commun*, vol. 7, no. 1, p. 13480, Nov. 2016, doi: 10.1038/ncomms13480.
  - [20] M. S. Evans and K. E. Viola-McCabe, 'Midazolam inhibits long-term potentiation through modulation of GABAA receptors', *Neuropharmacology*, vol. 35, no. 3, pp. 347–357, Mar. 1996, doi: 10.1016/0028-3908(95)00182-4.
  - [21] K. Kaila and J. Voipio, 'Postsynaptic fall in intracellular pH induced by GABA-activated bicarbonate conductance', *Nature*, vol. 330, no. 6144, pp. 163–165, Nov. 1987, doi: 10.1038/330163a0.
  - [22] J. M. Fritschy and H. Mohler, 'GABAA-receptor heterogeneity in the adult rat brain: Differential regional and cellular distribution of seven major subunits', *J. Comp. Neurol.*, vol. 359, no. 1, pp. 154–194, Aug. 1995, doi: 10.1002/cne.903590111.
  - [23] S. L. Dubovsky and D. Marshall, 'Benzodiazepines Remain Important Therapeutic Options in Psychiatric Practice', *Psychotherapy and Psychosomatics*, vol. 91, no. 5, pp. 307–334, Aug. 2022, doi: 10.1159/000524400.
  - [24] H. Ashton, 'The diagnosis and management of benzodiazepine dependence', *Current Opinion in Psychiatry*, vol. 18, no. 3, p. 249, May 2005, doi: 10.1097/01.yco.0000165594.60434.84.
  - [25] B. Pagni et al., 'Distinct and shared therapeutic neural mechanisms of mindfulness-based and social support stress reduction groups in adults with autism spectrum disorder', *Journal of Psychiatry and Neuroscience*, vol. 48, no. 2, pp. E102–E114, Mar. 2023, doi: 10.1503/jpn.220159.